XML 34 R24.htm IDEA: XBRL DOCUMENT v3.22.2
EQUITY SECURITIES PORTFOLIO INVESTMENT (Tables)
6 Months Ended
Jun. 30, 2022
Investments, Debt and Equity Securities [Abstract]  
Unrealized Gain (Loss) on Investments
Equity securities at fair value for the periods presented were comprised of the following:
Security TypeCostGross
Unrealized
Gain
Gross
Unrealized
Loss
Fair Value
(In thousands)
June 30, 2022:
Equity securities - Life Sciences Portfolio (Note 3)$44,854 $57,688 $(463)$102,079 
Equity securities - other common stock49,421 (25,157)24,266 
Total$94,275 $57,690 $(25,620)$126,345 
December 31, 2021:
Equity securities - Life Sciences Portfolio (Note 3)$56,037 $262,811 $(1,488)$317,360 
Equity securities - other common stock43,822 2,068 (1,472)44,418 
Total$99,859 $264,879 $(2,960)$361,778 
The following unrealized and realized gains or losses from our investment in the Life Sciences Portfolio are recorded in the change in fair value of equity securities and gain or loss on sale of equity securities, respectively, in the consolidated statements of operations:
Three Months Ended
June 30,
Six Months Ended
June 30,
2022202120222021
(In thousands)
Change in fair value of equity securities of public
   companies
$(32,458)$(35,057)$(204,098)$(29,683)
Change in fair value of equity securities without readily
   determinable fair value
— 46,154 — 77,956 
Gain on sale of equity securities of public
   companies
5,217 15,055 64,705 15,055 
Net realized and unrealized (loss) gain $(27,241)$26,152 $(139,393)$63,328